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Abstract
Background: Alstrom syndrome (AS) is a rare autosomal recessive disease characterized by
multiorgan dysfunction. The key features are childhood obesity, blindness due to congenital retinal
dystrophy, and sensorineural hearing loss. Associated endocrinologic features include
hyperinsulinemia, early-onset type 2 diabetes, and hypertriglyceridemia. Thus, AS shares several
features with the common metabolic syndrome, namely obesity, hyperinsulinemia, and
hypertriglyceridemia. Mutations in the ALMS1 gene have been found to be causative for AS with a
total of 79 disease-causing mutations having been described.
Case presentation: We describe the case of a 27-year old female from an English (Caucasian)
kindred. She had been initially referred for hypertriglyceridemia, but demonstrated other features
suggestive of AS, including blindness, obesity, type 2 diabetes, renal dysfunction, and hypertension.
DNA analysis revealed that she is a compound heterozygote with two novel mutations in the
ALMS1 gene – H3882Y and V424I. Examination of her family revealed that her phenotypically
unaffected mother and younger sister also had heterozygous mutations in the ALMS1 gene. In
addition to presenting these novel molecular findings for AS, we review the clinical and genetic
features of AS in the context of our case.
Conclusion: Two novel mutations in the ALMS1 gene causative for AS have been reported here,
thereby increasing the number of reported mutations to 81 and providing a wider basis for
mutational screening among affected individuals.
Background
Alstrom syndrome (AS; OMIM 203800) was first
described in 1959 and has an estimated prevalence of
<1:100 000 [1,2]. AS is an autosomal recessive multiorgan
disorder, characterized by childhood obesity, adult short
stature with initial accelerated childhood linear growth,
progressive cone-rod dystrophy leading to blindness, and
sensorineural hearing loss [3,4]. Endocrinologic compli-
cations include early-onset diabetes mellitus (typically in
the 2nd or 3rd decades), hyperinsulinemia (with associated
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acanthosis nigricans), hypertriglyceridemia, infertility
(hypergonadotrophic hypogonadism), and hypothy-
roidism [4-6]. Systemic fibrosis is commonly observed
[3]. The primary cause of mortality among young affected
patients is cardiac involvement from dilated cardiomyop-
athy whereas renal failure is the major cause of death
among the older subgroup [2,3].
Mutations in the ALMS1 gene were independently identi-
fied as causative for AS by two research groups [7,8].
ALMS1 encodes a protein of 4169 amino acids, which
includes a large tandem-repeat domain consisting of 47
amino acids (aa); the exact function of the ALMS1 protein
still remains unknown [7]. However, the ALMS1 protein
has been shown to be ubiquitously expressed and to local-
ize subcellularly [9]. It has been proposed that ALMS1 is
involved in the functioning of centrosomes or basal bod-
ies [9]. Although initial data revealed normal ciliary struc-
ture in fibroblasts from affected individuals with ALMS1
mutations, ALMS1 knockout mice demonstrated abnor-
mal ciliary structure that could be rescued with a prema-
turely truncated fragment of ALMS1 containing the N-
terminus [9,10]. Thus, the N-terminus of ALMS1 seems to
be crucial to normal ciliary structure [10]. To date, a total
of 79 disease-causing ALMS1  mutations have been
reported [11]. We report here the clinical and novel
molecular findings in a Caucasian kindred with Alstrom
syndrome from the United Kingdom and review the cur-
rent clinical and molecular genetic aspects of this condi-
tion.
Case presentation
In 2002, the 27-year old proband was referred to the lipid
clinic of a tertiary health care centre for evaluation of an
elevated triglyceride (TG) level of 59.1 mmol/L. Her prior
history included poor vision since birth, commencing
with the development of night blindness, eventually
resulting in legal blindness by the age of 17. She had
undergone a left nephrectomy at the age of 24 for a
perinephric abscess due to chronic pyelonephritis. Ultra-
sound evaluation revealed a normal-sized right kidney
with evidence of cortical scarring. Hypertension and dia-
betes subsequently developed at the ages of 25 and 26
years, respectively. She experienced learning difficulties in
school, but did not have sensorineural deafness. On phys-
ical examination, there was evidence of central obesity
with her body mass index (BMI) being 34.9 kg/m2. Her
blood pressure on antihypertensive treatment was 132/86
with a regular pulse of 80 beats per minute. There was no
evidence of poly- or syndactyly suggestive of Bardet-Biedl
syndrome. Hirsutism was present on the face, abdomen,
and arms. Ophthalmologic examination was notable for
retinitis pigmentosa and cataracts bilaterally.
Her family consisted of non-consanguineous parents,
both alive and well, as well as four siblings – three sisters
(aged 18, 26, 29 years) and one brother (aged 29 years),
who were also healthy. The family structure is outlined in
Figure 1.
Biochemical attributes and investigations
The proband's initial labwork at the time of consultation
revealed a plasma TG level of 20.6 mmol/L with a high-
density lipoprotein cholesterol (HDL-C) level of 0.56
mmol/L. Her fasting glucose and insulin levels on oral
antidiabetic therapy but not insulin were 14.2 mmol/L
and 68.1 mU/L (normal <10 mU/L), respectively, with a
HbA1C of 11.2%. Her creatinine was elevated at 255
µmol/L with overt proteinuria of 2.68 g/24 hours. Her
total alkaline phosphatase of 416 U/L (normal < 330 U/
L) demonstrated increases in both the liver and bone
isoenzymes. Abdominal ultrasound revealed fatty infiltra-
tion of the liver and splenic enlargement (14 cm in
length). Both her electrocardiogram and echocardiogram
were normal.
The results of lipoprotein analyses of the proband,
proband's mother and two sisters are shown in Table 1.
The proband demonstrated significant hypertriglyceri-
demia (TG = 20.6 mmol/L) and hypoalphalipoproteine-
mia (HDL-C = 0.56 mmol/L). Both the proband's mother
and older sister displayed mildly elevated plasma TG
whereas the younger sister tested had relatively normal
plasma TG. Plasma low density lipoprotein-cholesterol
(LDL-C) levels were higher among the mother and
younger sister compared to the others. The proband dem-
onstrated the lowest LDL-C and HDL-C levels of all four
members of the kindred examined.
Treatment
Treatment of the proband's hypertriglyceridemia required
the use of multiple therapies, including a low-fat diet (<
20 g fat per day), insulin (glargine 14 units/day), pioglita-
zone (45 mg/day), atorvastatin (40 mg/day), and omega-
3-acid ethylesters (Omacor) (2 g bid). As a result of ther-
apy, TG levels decreased by ~84% to 3.30 mmol/L and
HDL-C levels improved by ~252% to 1.41 mmol/L.
DNA isolation and sequence analysis
Informed consent was obtained from all available subjects
or their guardians, and the study was approved by the
institutional review board of the University of Western
Ontario (#07920E). DNA and lipoprotein analyses were
unavailable for the father, one sister (aged 18 years), and
brother (aged 29 years). Genomic DNA from the four
available study subjects was isolated from whole blood
(Puregene, Gentra Systems, Minneapolis, MN). Exons 1 to
23 of ALMS1 were amplified using the primers in Table 2.
The final volume of 50 µL contained 32 pmol of eachOrphanet Journal of Rare Diseases 2007, 2:49 http://www.OJRD.com/content/2/1/49
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primer, 0.2 mM each of dATP, dCTP, dGTP, and dTTP, 1.5
mM MgCl2, 50 mM KCl, 20 mM Tris-HCl (pH 8.4), and
2.5 units of Taq platinum DNA polymerase (Life Technol-
ogies, Mississauga, Ontario, Canada). DNA amplifica-
tions were performed with denaturing at 94°C for 5
minutes, followed by 30 cycles of a denaturing step at
94°C, an annealing step at 60°C, and an extension step at
72°C, each for 30 seconds. A final extension step at 72°C
was performed for 10 min. Amplification products were
electrophoresed on 1.5% agarose gels and purified with
the QIAEX II gel extraction kit (Qiagen, Inc., Mississauga,
Ontario, Canada). Purified DNA fragments were
sequenced by the chain termination method using the ABI
3730 Automated DNA Sequencer and analyzed using
Sequence Navigator Software (both from PE-Applied Bio-
systems, Mississauga, Ontario, Canada).
Identification of novel disease-causing ALMS1 mutation
Sequencing of genomic DNA from the affected proband
demonstrated no mutations in the coding regions of the
LPL gene (data not shown), but did reveal 2 novel mis-
sense mutations in the ALMS1 gene – a G→A transversion
at nucleotide 1381 of exon 6 and a C→T transversion at
nucleotide 11755 in exon 17. These mutations resulted in
the replacement of valine by isoleucine at codon 424
(V424I, exon 6) and histidine by tyrosine at codon 3882
(H3882Y, exon 17). The proband's mother was hetero-
zygous for the H3882Y mutation while the proband's
younger sister was heterozygous for the V424I mutation,
proving that the mutations were on opposite chromo-
somes in the proband. The proband's older sister was
unaffected both clinically and molecularly. See Figure 1.
The missense mutation V424I was subsequently geno-
typed in 200 healthy unaffected Caucasian controls using
the primer pair and PCR conditions for exon 6 amplifica-
tion. The amplified product was digested with restriction
enzyme AatII (New England Biolabs Inc., Ipswich, MA,
USA). All healthy controls were homozygous for G at
nucleotide 1381. Similarly, the missense mutation
H3882Y was genotyped in 200 healthy unaffected Cauca-
sian controls using the primer pair and PCR conditions for
exon 17 amplification. The amplified product was
digested using the restriction enzyme RsaI (New England
Biolabs Inc., Ipswich, MA, USA). Among the 200 controls,
only 1 control was found to be heterozygous at nucleotide
DNA sequence analysis of Alstrom syndrome mutations Figure 1
DNA sequence analysis of Alstrom syndrome mutations. Proband is indicated by the solid circle and arrow. Smaller 
symbols represent individuals from whom DNA was unavailable. There is no known consanguinity between the parents of this 
kindred. Electrophoretic tracings for exons 6 and 17 of the ALMS1 gene from the proband and available immediate relatives are 
shown. The proband is a compound heterozygote for the V424I and H3882 Y mutations while the mother demonstrates het-
erozygosity only for the H3882Y mutation and the younger sister demonstrates heterozygosity only for the V424I mutation. 
The older sister has no mutations in the ALMS1 gene.
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11755 C/T, giving an allele frequency of 0.9975 for the C
allele and 0.0025 for the T allele at this position, based on
the Hardy-Weinberg equation. This suggests that the sec-
ond heterozygote mutation, 11755 C→T, is present in the
general population, albeit at a very low frequency.
Literature review and case discussion
The distribution of AS is global without any gender predi-
lection. With an estimated prevalence of < 1:100 000,
only ~500 cases of AS have been reported in the literature
thus far [2-4,7,11-37]. Yet, a greater proportion of kin-
dreds of English descent have been noted in the literature.
Whether this is due to selection bias from kindreds in the
United Kingdom or North America having more readily
available health care access compared to kindreds from
developing nations is uncertain. Certainly, awareness of
AS is lacking despite the complexity and potential
lethality of this disorder. Moreover, in addition to child-
hood obesity, affected individuals may develop insulin
resistance, type 2 diabetes, and hypertriglyceridemia.
Thus, AS can be thought of as a rare genetic disorder with
several features similar to the common metabolic syn-
drome.
General clinical features
Prior to the recent discovery of ALMS1 mutations causa-
tive for AS, the diagnosis of AS was made solely based on
phenotype. However, AS exhibits a great degree of pheno-
typic variability, even within families, thereby creating dif-
ficulties for a universal definition of AS [17,18]. Recently,
Marshall et al defined AS using age-specific criteria [38].
See Table 3.
Neurosensory and cognitive features
Sensorineural hearing loss and congenital retinal dystro-
phy are two cardinal features of AS. In fact, pendular or
searching nystagmus and photodysphoria are often evi-
dent before the age of 1 yr. There is initial loss of cone
function followed by rod disintegration, ultimately lead-
ing to early blindness. By the age of 16, ~90% of affected
individuals are blind [38]. In addition, development of
subcapsular cataracts may contribute to vision loss [3,6].
Exudative retinopathy has also been reported in AS [12].
Meanwhile, ~80 % of affected individuals will develop
bilateral sensorineural hearing loss [3]. This usually
occurs at a later age in childhood and is characterized by
the initial loss of high frequency sounds. Progressive dete-
rioration in hearing occurs, and is sometimes accompa-
nied by conductive hearing loss due to chronic otitis
media or glue ear [3]. These early changes in neurosensory
capabilities have tremendous impact not only on the
social development of the child but also on his/her adap-
tation to the external environment.
Although delay of cognitive development is not a com-
mon feature of AS, delay in developmental milestones is
seen in ~45% of AS-affected children. Other neurologic
manifestations may include absence seizures and general
sleep disturbances [3]. The frequency of mood and psychi-
atric disorders in AS-affected individuals has not been
determined.
Anthropometric and growth measures
Individuals with AS often have distinctive facial features,
such as round face, deep-set eyes, thick ears, dental anom-
alies, hyperostosis frontalis interna, and premature frontal
balding. Their toes and fingers are typically short and
stubby with no polydactyly or syndactyly while their feet
are typically noted to be wide and thick [38].
Childhood obesity is present in over 95% of individuals
with AS [3]. However, both waist circumference and body
fat percentage (as measured using dual-energy X-ray
absorptiometry) negatively correlated with age, independ-
ent of BMI, indicating the possible recruitment of more
metabolically active fat stores [2]. The presence of hyper-
Table 1: Clinical and biochemical characteristics of the pedigree
Biochemical parameter Proband (II-2) Mother (I-1) Sister (II-1) Sister (II-3)
Total cholesterol (mmol/L) 7.40 7.70 5.78 6.79
Triglyceride (mmol/L) 20.6 2.61 3.80 1.78
VLDL- C (mmol/L) 4.62 0.92 1.09 0.58
VLDL-TG (mmol/L) 15.4 1.57 2.54 1.10
VLDL-TG/VLDL-C ratio 3.33 1.71 2.33 1.90
HDL-C (mmol/L) 0.56 0.94 1.04 1.72
LDL-C (mmol/L) 0.83 5.32 3.29 4.19
Apo A-1 (g/L) 1.25 1.20 1.45 1.59
Apo B (g/L) 0.91 1.59 1.16 1.22
Abbreviations: VLDL-C, very low density lipoprotein – cholesterol; VLDL-TG, very low density lipoprotein- triglyceride; HDL-C, high density 
lipoprotein – cholesterol; LDL-C, low density lipoprotein – cholesterolOrphanet Journal of Rare Diseases 2007, 2:49 http://www.OJRD.com/content/2/1/49
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phagia has been controversial [3,4]. Although childhood
is often accompanied by rapid growth with height above
the 50th percentile before puberty, most individuals dem-
onstrate a decreased adult height [2,3]. This height dis-
crepancy is supported by evidence for advancement of the
bone age by 1–3 years prior to puberty as described by
Marshall et al [3]. As well, abnormalities of the insulin
growth factor (IGF) system of affected patients have been
demonstrated [13]. Yet, the exact reasons for short stature
remain to be determined.
Endocrinologic features
Similar to the features of the metabolic syndrome seen in
the general population, patients with AS also demonstrate
hypertriglyceridemia and type 2 diabetes. Type 2 diabetes
is diagnosed in over 80% of individuals above the age of
16 while insulin resistance and hyperinsulinemia have
been demonstrated in individuals as young as 1 year old,
even prior to the onset of obesity [3,38]. Meanwhile,
hypertriglyceridemia is seen in ~50% of affected individu-
als, with acute pancreatitis secondary to hypertriglyceri-
demia occurring in ~5% [3]. Other endocrinologic
manifestations of AS include hypothyroidism, hypogo-
nadism (particularly among men), alterations in the onset
of puberty, ovarian cysts and hirsutism (among females),
and short stature with abnormalities in the IGF-growth
hormone system [3,13].
Table 2: Oligonucleotides for genomic amplification and sequencing of ALMS1
Exon Forward Primer Reverse Primer
1 GCACTGCGCCTAAGCTG CAGCCTCCACCCCCAAC
2 ATGTGAAAGGGCTTTATAAACTGG TTTTTCCATTCTTCATAGCTAAATCA
3 CAGTTAATGACTTAGCATGTTTTCCT TCCTTAACTCAAAAAGGGGAAAG
4 ACGTAAGTAAATAATCAATTTTCAGCA TCTAAGCCCCACCTCAAAGT
5 TTTCAGTGACATATGTATTTTTGTGTT TTCCCTTGGGAATTTTATTTTT
6 CTTCGTGTGTGGGAGCTGAG CAATACTGAAAAAGGCCACGTT
7 TGGGCATTAATGAGTCTTTTTC TTTTCACAAGGTATCCGTAAGTAGG
8 GCTTTTTAAAGGCTCAAAGCTG TCTCTCTATGTGAGTAGGAAGTAGAGG
8 TGACCAGACAACTGGCATGT GACTGTCTGCTAAGTCCTGTGG
8 TTCTTACTCACAAAGAGAAAAGCCTA GGGCAGCCAATACAGAAACA
8 TTTCCCTGAAGAAGCTCTGAA TGGCAAGGTCTGTTGGTAGA
8 TCACAAAGAGAGAAGCCTGGT AGCTGGTGTGCCAGTTGTCT
8 TTCAGTTGCCTCTGAACCAG TGTGGCAAGACCTGTTGGTA
8 CACACACAGAGAAGCCTGGT AAAGGTCCTGCTGGTATGTCA
8 TCCATTGTTTCTGGACCTACTG ATCTGGCAACTCTTGCTGGT
8 ACTGTAACTTCCTCTTTCTATTCACAT TCTCAGTCTTCCGGTCACCT
8 AGCAGGAGTTGCCAGATGTT CTGGTTTTCCAGTATTCACATCA
8 AAAGATTTCAGCTGTCCCTGA CTGCATCCTGGATTTCTTCA
8 CTCAGGCTGATGACAGAGTTG CCCAATGGTTCCACTACACC
8 GAGCAAAGTCAGTATGGCATTAGA TGGCTAAGCTTCCTCAAAACA
9 TCTTCTGTGTTGCAATTGTTGA TTCCATCACCCATTCTTTCA
10 TTGGACTACTTCAAATAAGAACCTG GACGGCATTTGTGATGAAGA
10 ACCTGCTTTTGTGCCACCTA CTTGGTCTGCCCATGCTAAT
10 CCAGTACCAGGGCAAATTGT GGAAGGGGAAAATGGTGTTT
10 ACCTTCCGTCTCCCATTTCT TCCTGTGCTACAGGTTTACTGG
10 GCTTCTAAAGCGAGGATGAA CCCCCAAGAACCGATATCTA
11 TTCCTTGAAACCACTTTTGGA GAAAGACACAACCACAAATTTCTAA
12 GAAGGCATTCCATATTTGTTCA GCACTGGACTTTTGTCACTCC
13 TCATAGAATTGGTCTAAGAGGCAAA AAGATTGGATAGTAATCTCATTTAGGA
14 ATGGGTTTGGGGTTTTGTTT GAGCTGAAGACAGCAAGAAGAA
15 AACAAAGCCTTTCACATAATACG CACTGACCCTCACATACACAC
16 GCAGGCAGTGAATTTTCTGAT TTTTGGATAATCTCTAACTTGACTTTT
16 CCAGAATAAAGAGCCTCAGCA TTTTTAAGCTCGCCTGTATTTTT
16 GCGGTTTAAAAGCCTAGAGAAA TTTTCACCTGTGTGCAAAGC
17 TGAATTGGATTAGAAAGAGGACTTG TCTTACATGTTTAAGAGCCATTTCA
18 TCCCACACAAAGGGATTGTA ATCGCAGGGGACTTGAAAT
19 CTGGGTGGGGCTGTAAAAA CCAAGTCACAGAGCCAGCTT
20 GCATATGGAGAGTAGATTGCATCA TGGGCTGGCCTTTAGCAG
21 GGTAGGGGCACCAAGTCCTA CAGAGCTCCCGACCACTTG
22 GATGAGCTCCTGGAGAGTGG GGCAACGTGTTTTCTCCATT
23 GGCATCTGCCTCTGATGG AAGGATTCTGCTTCTCTAGGTTCAOrphanet Journal of Rare Diseases 2007, 2:49 http://www.OJRD.com/content/2/1/49
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Cardiorespiratory features
Dilated cardiomyopathy (DCM), affecting ~60% of indi-
viduals, can occur at any age, but most typically during
infancy. Although DCM is the most common underlying
cause of death in the infantile period, survival with infan-
tile-onset of DCM tends to be better than that for adult-
onset DCM. Marshall et al showed that while one-third of
adult-onset DCM patients died, ~74% of infantile-onset
DCM patients survived [3]. However, children and adults
who have survived infantile-onset DCM are still suscepti-
ble to sudden recurrences [38]. In addition to cardiac
problems, AS-affected patients can have a variety of respi-
ratory problems, including chronic asthma, sinusitis/
bronchitis, alveolar hypoventilation and recurrent pneu-
monia [3].
Gastrointestinal and genitourinary involvement
Hepatic involvement in AS was first described in 1991
[39]. Approximately 80% of patients affected with AS may
have hepatic involvement, ranging from mild elevation in
liver transaminases to hepatic steatosis to overt cirrhosis
with portal hypertension [3,30,31]. Other gastrointestinal
effects include upper gastrointestinal pain, chronic
diarrhea, constipation, and gastroesophageal reflux [3].
Renal insufficiency occurs in ~50% of AS-affected individ-
uals. Whether hypertension is a consequence of renal
insufficiency or contributes to renal insufficiency is uncer-
tain, but it is present in ~30% of individuals [3]. Urologic
dysfunction is common in both men and women and can
be manifest as urge incontinence, poor flow, urinary
retention, or difficulty initiating voiding [3]. Urologic
anatomical abnormalities can also occur in AS, including
calyceal deformities, narrowed ureteropelvic angles,
dilated ureters, and misalignment of the kidneys [6].
Differential diagnosis
It remains important to distinguish AS from other disor-
ders characterized by childhood obesity and retinal dys-
trophy, such as the Laurence-Moon and Bardet-Biedl
syndromes. Normal mentation and lack of poly/syndac-
tyly help to distinguish AS from Bardet-Biedl, while deaf-
ness and the absence of spastic paraparesis help to
differentiate AS from Laurence-Moon. Refsum disease is a
rare disorder characterized by hearing loss, visual loss,
and hepatic involvement, but also includes several fea-
tures not associated with AS [40]. See Table 4 for clinical
features of these disorders.
Table 3: Diagnostic criteria for Alstrom syndrome [38]
Age (years) Major Criteria Minor Criteria Other supportive evidence Diagnosis
≤ 2* • ALMS 1 mutation in 1 allele 
and/or family history of AS
• Vision (nystagmus, 
photophobia)
• Obesity
• DCM/CHF
• Recurrent pulmonary infections
• Normal digits
• Delayed developmental milestones
2 major criteria
OR
1 major + 2 minor criteria
3–14 • ALMS 1 mutation in 1 allele 
and/or family history of AS
• Vision (nystagmus, 
photophobia, decreased 
acuity, cone dystrophy by 
ERG**)
• Obesity and/or insulin 
resistance
• (History of) DCM/CHF
• Hearing loss
• Advanced bone age
• Hepatic dysfunction
• Renal failure
• Recurrent pulmonary infections
• Normal digits
• Delayed developmental milestones
• Hyperlipidemia
• Scoliosis
• Flat wide feet
• Hypothyroidism
• Hypertension
• GH deficiency
• Recurrent UTI
2 major criteria
OR
1 major + 3 minor criteria
≥ 15 • ALMS 1 mutation in 1 allele 
and/or family history of AS
• Vision (legal blindness, 
history of nystagmus in 
infancy/childhood, cone and 
rod dystrophy by ERG)
• Obesity and/or insulin 
resistance and/or DM2
• (History of) DCM/CHF
• Hearing loss
• Hepatic dysfunction
• Renal failure
• Short stature
• Males – hypogonadism
• Females – irregular menses 
and/or hyperandrogenism
• Recurrent pulmonary infections
• Normal digits
• History of developmental delay
• Hyperlipidemia
• Scoliosis
• Flat wide feet
• Hypothyroidism
• Hypertension
• GH deficiency
• Alopecia
• Recurrent UTI or urinary dysfunction
2 major + 2 minor criteria
OR
1 major + 4 minor criteria
*These diagnostic criteria should be re-evaluated when the patient becomes older
** ERG to be conducted only if the child is old enough for testing
Abbreviations: AS, Alstrom syndrome; DCM/CHF, dilated cardiomyopathy/congestive heart failure; ERG, electroretinogram; GH, growth hormone; 
UTI, urinary tract infections; DM2, type 2 diabetes.Orphanet Journal of Rare Diseases 2007, 2:49 http://www.OJRD.com/content/2/1/49
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Genetic features of AS
AS is an autosomal-recessive disease that demonstrates
intrafamilial and interfamilial variation. To date, a total of
81 disease-causing ALMS1 mutations have been reported,
including the 2 reported from our group [11]. A schematic
representation of the normal ALMS1 gene and the ALMS1
mutations causative of AS are shown in Figures 2, 3, 4.
Affected individuals of most kindreds demonstrate com-
pound heterozygosity with the majority of ALMS1 muta-
tions reported being nonsense. Approximately 40% of all
known ALMS1 mutations occur in exon 16 while other
ALMS1 mutational hotspots include exon 10 (23%) and
exon 8 (21%) [11]. Mutations in exon 16 have correlated
with a more severe disease phenotype, manifest as early
onset of retinal degeneration before the age of 1 year (p =
0.02), presence of urologic dysfunction (p = 0.02), occur-
rence of dilated cardiomyopathy (p = 0.03), and develop-
ment of diabetes (p = 0.03). Meanwhile, the severity of
renal disease in AS has correlated with mutations in exon
8 [11].
Among 250 AS-affected individuals examined, 15 synon-
ymous single nucleotide polymorphisms (SNPs), 51 non-
synonymous SNPs, and a deletion of 3 nucleotides in
exon 8 have also been described. Using prediction mode-
ling, Marshall et al have determined that 8 of these vari-
ants are disease-causing [11]. The most common ALMS1
mutation is c.10775delC, which is observed in 50% of
reported English kindreds. Similarly, haplotype sharing
has been demonstrated amongst members of Turkish kin-
dreds, indicating the possibility of separate founder effects
in both the English and the Turkish kindreds [11].
Discussion of our case
Our results indicate that ALMS1 mutations of V424I and
H3882Y are the molecular basis for the Alstrom pheno-
type in the proband presented here. The H3882Y muta-
tion was present in only 1 of 200 normal healthy controls
while the V424I mutation was absent in all 200 controls.
These two disease-causing mutations have not been
reported before and represent the first mutation reported
for exon 6 and the second reported for exon 17 [11]. Inter-
estingly, the predicted frequency of homozygotes for the
Normal ALMS1 gene structure* Figure 2
Normal ALMS1 gene structure*. * Figure 2 is not drawn to scale.
Nucleotide      438     564   760      878  1351 1452     1546                            7654                          7788      9653                            10021      10327          11661            11986       12412        12576 
9895         10192        10498                  11782      12228     12476        12928
23 19 20 21 22  17 18  16 13 14 15  12 11 10 9 8 7 6 5 4 2 3 1
Table 4: Differential diagnosis for Alstrom syndrome [41, 42]
Alstrom syndrome Laurence- Moon 
syndrome
Bardet- Biedl syndrome Refsum disease
I n h e r i t a n c e A RA RA RA R
Childhood Obesity + + + -
V i s u a l  I m p a i r m e n t ++++
Sensorineural Deafness + - - +
Short Stature + - -/+ -
Diabetes Mellitus + - + -
Renal Disease + - + -
Polydactyly/syndactyly - - + +
Mental Delay - + + +/-
Hypogonadism + + + -
Dilated Cardiomyopathy + - -/+ -/+
Other Hepatic Involvement Spastic paraplegia - Anosmia Dysmorphic 
features Cerebellar ataxia 
Polyneuropathy
Abbreviations: AR, autosomal recessiveOrphanet Journal of Rare Diseases 2007, 2:49 http://www.OJRD.com/content/2/1/49
Page 8 of 10
(page number not for citation purposes)
H3882Y mutation would be 1 in 160 000, signifying that,
if homozygotes are affected, AS may indeed be more prev-
alent than previously thought.
To date, with the 2 missense mutations of our kindred,
there are a total of 10 missense AS-causing mutations.
Marshall et al showed that the majority of kindreds
affected by AS, as in our kindred, demonstrate compound
heterozygote mutations [11]. The V424I mutation local-
izes to the N-terminus of the ALMS1 protein while the
H3882Y mutation localizes to the C-terminus of the pro-
tein [7]. Since even fragments of the N-terminus have
been shown to be able to normalize the abnormal ciliary
structure of ALMS1 knockout mice, it would be expected
that isolated heterozygous mutations still including the
relatively intact N-terminus would not necessarily result
in significant clinical findings, as evidenced in our
proband's mother and younger sister [10]. The functional
importance of the C-terminus remains to be determined.
Importantly, no correlations could be drawn between the
Reported ALMS1 Mutations for Exons 6, 8, 10, 12, 17, 18* Figure 4
Reported ALMS1 Mutations for Exons 6, 8, 10, 12, 17, 18*. * Figure 4 is not drawn to scale. The two novel mutations 
found in this study are shaded in gray. Other mutations not included in the figure are AC074008.5:g.124455_125899del and 
10483C>T.
6 8
1769T>A
1789delG
68
2141_2142delCT 
2164A>T
2179dupT
2225_2226insA
3425C>G
4937C>A
6305C>A
6571_6574delTCAC 
6590delA
6648T>G 
6800T>A
7132dupA
7304_7305delA
7373C>T
7374_7375delAG 
7534C>T
8782C>T
8315delC
8008C>T
8045C>G
8177-8187del 
8164C>T
8383C>T
8394dupA
8656C>T
8938C>T
8987T>G 
9011_9021del 
9194T>G 
9199G>T 
5154G>C
1381G>A
9163A>T 8506G>T 
9328C>T
9541C>T
10
7942C>T
11663T>C
11755C>T
11856delC
4   17         18
       Nucleotide  1352     1452         1547                                                                                    7654                                       7789                9653                     9896   10021              11662     11782 11783  11986 
412
9904dupC
9254delA
Reported ALMS1 Mutations for Exon 16* Figure 3
Reported ALMS1 Mutations for Exon 16*. * Figure 3 is not drawn to scale.
Nucleotide        10499                                                                                                                                                11661 
11207C>A
10843_10844delCA 
11005C>T
11107C>T
10885C>T
11313_11316delTAGA 
11314dupA
11385delT
11416C>T
11460C>G 
10975C>T
10499A>T
10568_10569delAT 
10609_10610delGAinsT; 10614G>A 
10674_10677delAGAA 
10775delC
10992G>A 10539_10557insTGTCTTTCCAAGATTGGAA 
10513A>T
10535G>A
10549C>T
10579_10580delAT 
10753C>T
10780C>T
10831_10832delAG 
10945G>T 
11080A>T
10849G>T 
16
11116_11135del 
11316_11319delAGAG 
11449C>T
10825C>T
10790_10791delTG 
6 8Orphanet Journal of Rare Diseases 2007, 2:49 http://www.OJRD.com/content/2/1/49
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presence of a single ALMS1  mutation, as seen in the
mother and younger sister, and abnormalities in any of
the lipid parameters examined.
Hypertriglyceridemia was evident in our proband and is a
common finding among individuals affected with AS. Our
proband had no documented episodes of pancreatitis, but
was at high risk for pancreatitis given her significant
hypertriglyceridemia. There can be multiple factors con-
tributing to hypertriglyceridemia among AS-affected
patients, including insulin resistance or diabetes, liver
dysfunction, renal dysfunction, dietary factors, and alco-
hol intake. However, examination of a group of AS-
affected individuals demonstrated no significant correla-
tions between hepatic or renal function, BMI, or degree of
glucose intolerance and high TG levels. Instead, there was
indeed a major correlation between hyperinsulinemia
and hypertriglyceridemia in that study [5]. Our proband
demonstrated significant hypertriglyceridemia, accompa-
nied by insulin resistance (type 2 diabetes), elevated BMI,
and renal dysfunction. A multifaceted treatment approach
resulted in improvements in TG and HDL-C to 3.30
mmol/L and 1.41 mmol/L, respectively, demonstrating
that it is possible to effectively treat lipid abnormalities
among AS-affected individuals.
The correlation of mutations in exons 6 or 17 to pheno-
type remains to be determined. Interestingly, our proband
did not have sensorineural deafness, which typically
occurs in ~84% of affected individuals [11]. No genotype-
phenotype correlations have been made for sensorineural
deafness [11]. However, it is possible that mutations in
exon 6 or 17 may not be associated with sensorineural
deafness although further kindreds with these mutations
are required to substantiate this possibility. Yet, the muta-
tions in this proband seem to have resulted in an "inter-
mediate-severity" phenotype as judged by an early onset
of retinal degeneration, severe renal dysfunction, and sig-
nificant elevation of TG levels, but a later development of
diabetes and a lack of dilated cardiomyopathy.
Conclusion
We have reported here two novel missense mutations in
the ALMS1 gene causative for Alstrom syndrome in an
English kindred. These extend the mutational spectrum in
AS and provide a resource for mutational screening. Fur-
thermore, we hope that these mutations may eventually
add insight into the function of the ALMS1 protein and
contribute to the understanding of the phenotypic variety
observed among AS-affected individuals.
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